Back in February, we announced our intention to name our combined Company Allergan, with the Actavis name remaining in select geographies. However, before we can make these changes, we will need shareholder approval. We expect to receive the necessary approval in May and plan to rollout of the Allergan name shortly after. In the meantime, we will continue to operate under our legacy names in all markets.